Antibiotic prescription preferences in paediatric outpatient setting in Estonia and Sweden by Jana Lass et al.
a SpringerOpen Journal
Lass et al. SpringerPlus 2013, 2:124
http://www.springerplus.com/content/2/1/124RESEARCH Open AccessAntibiotic prescription preferences in paediatric
outpatient setting in Estonia and Sweden
Jana Lass1,2*, Viveca Odlind3, Alar Irs4,5 and Irja Lutsar1Abstract
Aims of the study were to compare the paediatric outpatient antibiotic use in two countries with low overall
antibiotic consumption and antibacterial resistance levels - Sweden and Estonia - and to describe the adherence to
Estonian treatment guideline.
All prescriptions for systemic antibiotics for children less than 18 years during 2007 from the Swedish Prescribed
Drug Register and Estonian Health Insurance Fund database were identified to conduct a descriptive drug
utilisation study.
The total paediatric antibiotic use was 616 and 353 per 1000 in Estonia and Sweden, respectively. The greatest
between country differences occurred in the age group 2 to 6 years –Estonian children received 1184 and Swedish
children 528 prescriptions per 1000. Extended spectrum penicillin amoxicillin (189 per 1000) or its combination with
beta-lactamase inhibitor (81 per 1000) and a newer macrolide clarithromycin (127 per 1000) were prescribed most
often in Estonia whereas narrow spectrum penicillin phenoxymethylpenicillin (169 per 1000) and older generation
macrolide erythromycin (21 per 1000) predominated in Sweden. For acute bronchitis, 17 different antibiotics (most
commonly clarithromycin) were prescribed in Estonia despite the guideline recommendation not to use antibiotics.
The higher rate of antibiotic use especially of extended spectrum antibiotics in Estonia compared to Sweden
emphasizes the need for national activities to promote appropriate use of antibiotics while treating children, even
when the overall antibiotic consumption is low.Introduction
Antibiotics are among the most prescribed medicines in
children across Europe including Estonia and Sweden
(Olsson et al. 2011; Lass et al. 2011; Clavenna & Bonati
2009) but great quantitative and qualitative variations in
their prescription profile have been shown between coun-
tries (Clavenna & Bonati 2011; Rossignoli et al. 2007).
As of many examples for quantitative differences, in
Italy the antibiotic prescription rate was twice as high
compared with Denmark (Lusini et al. 2009). Also the
children in British Columbia received substantially more
antibiotic prescriptions than Danish counterparts (Marra
et al. 2007) and in the Netherlands the prevalence of the
use of anti-infective drugs in children was much lower
than in the UK and Italy (Sturkenboom et al. 2008). At
the same time, studies for qualitative variations of pre-
scribing antibiotics to children are outnumbered. Only* Correspondence: Jana.Lass@kliinikum.ee
1Institute of Microbiology, Tartu University, Tartu, Estonia
2Pharmacy Department, Tartu University Clinics, Tartu, Estonia
Full list of author information is available at the end of the article
© 2013 Lass et al.; licensee Springer. This is an
Attribution License (http://creativecommons.or
in any medium, provided the original work is plimited data of few countries are available on the most
frequently prescribed antibiotics (Clavenna & Bonati 2011;
Rossignoli et al. 2007).
Amoxicillin has been reported to be the most frequently
prescribed antibiotic in the Netherlands and Canada
whereas the use of amoxicillin with clavulanic acid
prevailed in Italy (Clavenna & Bonati 2011).
Estonia and Sweden are Northern European countries
with relatively low antibiotic resistance among microorgan-
isms commonly managed in outpatient setting (European
Centre for Disease Prevention and Control 2009). Also the
total antibiotic use in outpatient settings in Estonia and
Sweden has been shown to be similar. In fact, when
expressed in defined daily doses per 1000 inhabitants in
2002, total antibiotic use was lower in Estonia than in
Sweden (Goossens et al. 2005).
Almost two decades ago, a study comparing antibiotic
use in Swedish and Estonian university hospitals found
that the frequency of antibiotic use in these countries
was in general similar but differences in the prescription
preferences were observed (Kiivet et al. 1998).Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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paediatric antibiotic prescription preferences in these
countries.
Most antibacterial drugs are prescribed to children for
the treatment of common paediatric conditions such as
upper respiratory tract infections and acute otitis media
(AOM) (Lusini et al. 2009; Finkelstein et al. 2000). Both
conditions are often self-limiting viral infections, typic-
ally not benefitting from antibiotic therapy (Rossignoli
et al. 2007; Moro et al. 2009; Hare et al. 2006) and are
thus major causes of inappropriate antibiotic prescribing
in the outpatient setting (Nitzan et al. 2010) and potential
targets for interventions to improve the use of antibiotic
medicines. Sweden has a nationwide government-funded
multidisciplinary programme STRAMA (http://www.
strama.se) to fight against the over- and misuse of
antibiotics, no similar programme exists in Estonia. As
a positive result, after initiation of STRAMA, the out-
patient paediatric antibiotics use fell 34% in Sweden
between the years 1992 and 2002 from 1159 to 764 pre-
scriptions per 1000 (Högberg et al. 2005).
The first aim of this report was to compare the general
antibiotic consumption rates and prescription prefer-
ences in paediatric outpatient settings in Estonia and
Sweden. Secondly, we describe the selection of antibi-
otics for the most common diagnoses by physicians in
Estonia and adherence to treatment guideline.
Methods
Setting
Estonia and Sweden both have government supported
public health services. In Estonia, the general practi-
tioners (GP) provide primary care and access to health
care is fully covered to all subjects below 19 years. Anti-
biotics are fully reimbursed for children younger than 4
and 90% of the price of medicines is reimbursed from 4
to 16 years. Exceptionally, for cystic fibrosis patients,
100% of the ciprofloxacin price is reimbursed regardless
of age.
In Sweden, the cost of antibiotics – like most other
prescription medicines – is partly reimbursed. If the
total cost for medicines during one year has surpassed a
ceiling of SEK 1800 (around €200), the cost is fully
reimbursed.
In both countries antibiotics are exclusively prescrip-
tion medicines.
Design
We conducted a descriptive drug utilisation study based
on the Estonian Health Insurance Fund (EHIF) and
Swedish Prescribed Drug Register (SPDR) database. Both
are nationwide prescription databases, containing elec-
tronically submitted data of all prescription medicines
dispensed by the pharmacies to individuals receivingambulatory care. The Estonian database contains indi-
vidual patient and physician identification numbers and
is diagnosis-linked. The Swedish database contains prod-
uct identification and patient’s age but no information
with regard to dose or indication.
We identified all prescriptions for systemic antibacter-
ial drugs (Anatomical Therapeutic Chemical (ATC) code
J01) released for children aged less than 18 years be-
tween January 1 and December 31, 2007, from both
databases.
We used the following data from the EHIF: patient’s
age, prescriber speciality, drug data (package code, ATC
Code, name of the active substance, brand name) and in-
formation on subsequent diagnoses.
From the Swedish database aggregated data on the
number of prescriptions for each active substance for
each age group was obtained.
We stratified the children by age based on the Inter-
national Conference of Harmonization guideline as
newborns and infants (0-1,99 years), pre-school children
(2–5,99 years), school children (6-11,99 years) and ado-
lescents (12–17,99 years) (2000).
Population data were obtained from the Statistics
Estonia (http://pub.stat.ee/px-web.2001/Database/
Rahvastik/databasetree.asp) and from Statistics Sweden
(http://www.scb.se).
We used the Estonian national guideline for diag-
nosing and treating common infections in outpatient
settings in Estonia, approved in 2005 http://www.
ravijuhend.ee.
In Sweden, recent national guidelines on the treat-
ment of acute otitis media, rhinosinusitis, pharyngotonsillitis
and lower respiratory infections have been published by the
Medical Products Agency (http://www.lakemedelsverket.se).
Data analysis
We expressed the paediatric antibiotic use as number of
prescriptions for systemic antibiotics (ATC code J01) per
1000 children aged until 18 years (included) in the popu-
lation/year and calculated the 95% confidence intervals
(CIs) by using R64 software (http://www.r-project.org/).
Results
Antibiotic consumption - Estonia versus Sweden
The paediatric population in 2007 was 7.5 times smaller
in Estonia (n = 258,515) as compared with Sweden (n = 1,
933, 920). At the same time the total paediatric antibiotic
use was almost twice as high - 616 per 1000 (95% CI 613
to 619) in Estonia versus 353 per 1000 (95% CI 352 to
354) in Sweden (Figure 1).
The highest prescription rate in Estonia was found
among 2 to 6 year old children whereas in Sweden it was
highest among those less than 2 (Figure 1). The greatest
difference between the two countries occurred in
Figure 1 Number of prescriptions per 1000 children of systemic antibacterials (ATC group J01) by age groups in Estonia and Sweden.
*Includes monobactams (J01DF), carbapenems (J01DH), aminoglycosides (J01G), quinolones (J01M) and other antibacterials (J01X).
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received more than twice as many prescriptions compared
with their Swedish counterparts (1184 vs. 528 per 1000
children). Adolescents had the lowest rate of antibacterial
prescriptions in both countries but the difference in favour
of Sweden as in all other age groups was observed.
Prescription by antibiotic classes
A total of 55 different active substances (22 in Estonia
and 50 in Sweden) were used. However, 90% of prescrip-
tions were covered by 8 agents in both countries.
Penicillins were the most widely prescribed antibiotics
with the similar prescription rate in both countries
(Figure 1) but the ratio of penicillins of all prescriptions
was significantly greater in Sweden than in Estonia (74%
vs. 49%). In addition, the qualitative selection of penicil-
lins differed considerably - extended spectrum penicillin
amoxicillin or its combination with beta-lactamase in-
hibitor (amoxicillin + clavulanic acid) were commonly
prescribed in Estonia whereas narrow spectrum penicillins
(e.g. phenoxymethylpenicillin) predominated in Sweden
(Figure 2, Table 1). Penicillinase resistant penicillins
(dicloxacillin and flucloxacillin) had a considerable use
in Sweden, but were not available in Estonia.
Macrolides accounting for 24% of prescriptions were
extensively used in Estonia (149 prescriptions per 1000)
in all age groups, with the highest rates observed among
children aged 6 to 17 years whereas in Sweden they were
used less frequently (29 prescriptions per 1000; 8% of
all prescriptions) (Figure 1). The types of macrolides
also differed between countries – Estonian physicians
preferred claritromycin (127 per 1000; Sweden 0.6 per
1000) but erythromycin was mainly prescribed in
Sweden (21 per 1000, Estonia 3 per 1000).
Cephalosporins were the third most commonly used
agents in Estonia (16%; 100 per 1000) but were less oftenprescribed in Sweden (7.5%; 26 per 1000) (Figure 1).
First generation cephalosporins (cefalexin, cefadroxil)
were prescribed with equal frequency in both countries
whereas the second-generation cephalosporins (cefuroxime,
cefprozil) were more frequently used in Estonia compared
to Sweden (68 vs. 1.4 per 1000, respectively). No third- or
fourth-generation cephalosporins were used in Estonia but
they were prescribed occasionally in Sweden.
Among other antibacterials, nitrofurantoin, quinolones
and lincosamides were rarely prescribed in either coun-
try. Sulfonamides and trimetoprim was more often pre-
scribed in Estonia (8%; 50 per 1000) than in Sweden
(4.7%; 17 per 1000). Aminoglycosides were not pre-
scribed for Estonian children and very rarely used in
Sweden. In Swedish adolescents, tetracyclines were used
twice as often than in Estonian 12-17 year olds (30 vs.
16 per 1000; Figure 1).
Selection of antibiotics by Estonian physicians and
adherence to treatment guideline
GPs were responsible for the majority (73%), paediatri-
cians for 12% and ear, nose and throat (ENT) physicians
for 9% of prescriptions. Other specialists made the
remaining 6% of all prescriptions.
The most common diagnoses for which antibiotics
were prescribed were acute bronchitis (ICD-10 code J20;
20% of all antibiotic prescriptions), non-suppurative
AOM (H65; 16%) and acute tonsillitis (J03; 12%). Other
common diagnoses were acute laryngitis and tracheitis
(J04; 8.3%), acute pharyngitis (J02; 7.8%), croup and
epiglottitis (J05; 7.2%); acute sinusitis (J01; 5.9%) and
diseases of the genitourinary system (N00-N99; 3.8%)
There were 2% of prescriptions for skin and soft
tissue infections (L.00-L.30) and 2.4% for pneumonia
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Figure 2 Proportion of different penicillins used in Estonia and Sweden.
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scribed in Estonia despite the guideline recommendation
not to use antibiotics at all. Clarithromycin was the most
commonly prescribed antibiotic, followed by amoxicillin
and amoxicillin + clavulanic acid (Table 2).
For non-suppurative AOM, also 17 different antibi-
otics were prescribed, most commonly amoxicillin (in
accordance with the guidelines) and amoxicillin +
clavulanic acid, followed by cefprozil, cefuroxime and
clarithromycin. There were 213 prescriptions per 1000
children less than 2 years of age and 87 prescriptions
per 1000 for 2 to 18 years old children.
For acute tonsillitis, amoxicillin was most commonly
prescribed, followed by phenoxymethylpenicillin; both
were recommended by guidelines as first line treatment
(Table 2).
The antibiotic preference for acute bronchitis was
the same between GPs, paediatricians and ENT spe-
cialists. Similarly, for non-purulent AOM, the choices
coincided, except that GPs and ENT physicians prefer-
ably prescribed the second-generation cephalosporin
cefprozil whereas paediatricians preferred cefuroxime.
For acute tonsillitis, GPs predominantly prescribed amo-
xicillin, paediatricians prescribed phenoxymetylpenicillin
and amoxicillin equally often whereas ENT physicians
predominantly prescribed clarithromycin (Table 2).
The antibiotics prescriptions for Estonian children
were equally divided between male and female sub-
jects. Slightly more prescriptions were purchased
for boys less than 2 years old compared to the girls
at the same age and for adolescent girls compared
to the adolescent boys (55% vs 45% for both age
groups).
The frequency of prescriptions for systemic antibiotics
per unique child purchased in 2007 in Estonia is de-
scribed in the Table 3.Table 1 Antibiotic agents prescribed most commonly - numb
all prescriptions (in the brackets)
Estonia
1 Amoxicillin 189 (30.6)
2 Clarithromycin 127 (20.6)
3 Amoxicillin + clavulanic acid 81 (13.2)
4 Sulfamethoxazol + trimethoprim 46 (7.4)
5 Cefprozil 35 (5.6)
6 Cefuroxime 34 (5.5)
7 Cefadroxil 32 (5.2)
8 Phenoxymethylpenicillin 24 (4)
9 Azitromycin 15 (2.4)
10 Doxycyclin 6 (1)
Others 28 (4.5)Discussion
While comparing antibiotic consumption in ambulatory
setting in Estonia and Sweden we observed that in both
countries the paediatric antibiotic use is in low ranges
(616 in Estonia and 353 in Sweden) as compared to
Spain or France (over 1500 and 1000 prescriptions per
1000 children, respectively) (Sharland 2007). However,
the Estonian children received twice as many prescrip-
tions for antibacterials compared to Swedish counter-
parts. Secondly, similarly to a study conducted almost
two decades ago in Estonian and Swedish University
Hospitals (Kiivet et al. 1998) we noted differences in anti-
biotic prescription preferences in the two countries –
most conspicuously, phenoxymethylpenicillin covered half
of the prescriptions in Sweden, whereas amoxicillin and
clarithromycin were preferred in Estonia.
The quantitative differences in antibiotic use between
countries could not be explained by dissimilarities in re-
sistance level of common outpatient microorganisms,
which have been reported to be low in general in both
countries. For example, in 2005 to 2009, the proportion
of methicillin resistant S. aureus has ranged between 2%
to 9% in Estonia and 0.5% to 1% in Sweden; no penicillin
resistant S. pneumoniae among invasive strains has been
reported in Estonia and the rate in Sweden was 0.1% to
2.5% (European Centre for Disease Prevention and Con-
trol 2999). A slightly higher number was reported among
colonising strains of S. pneumoniae in Estonia; 6% of
all isolates of S. pneumoniae were either penicillin-
nonsusceptible Streptococcus pneumoniae (PNSP) or
resistant to erythromycin, but none showed resistance
to penicillin (Tamm et al. 2007). Macrolide resistance
of S. pyogenes is about 5% in Estonia (European Centre
for Disease Prevention and Control 2999).
Our study brought also out the qualitative differences
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Table 2 Most common diagnoses in Estonia for which antibiotics are prescribed, guideline recommendations and the selection of drugs by physician speciality –









GPs Paediatricians Ear, nose and throat physicians
Acute bronchitis
(n = 31,670)
Antibiotics not indicated NA Clarithromycin
(45%; n = 11,658)
Clarithromycin (50.5%; n = 2,342) Clarithromycin (59%; n = 39)
Amoxicillin
(28%; n = 7,243)
Amoxicillin (22%; n = 1,040) Amoxicillin
+ clavulanic acid (9%; n = 418)
Amoxicillin (18%; n = 12) Amoxicillin + clavulanic acid
(9% n = 6)
Amoxicillin + clavulanic




Amoxicillin or penicillin Macrolide if
penicillin allergy
Amoxicillin
(46%; n = 7,616)
Amoxicillin (49%; n = 1,432) Amoxicillin (41%; n = 2,522)
Amoxicillin + clavulanic
acid (24%; n = 3,859)
Amoxicillin + clavulanic acid
(17%; n = 497)
Amoxicillin + clavulanic acid (21%; n = 1306)








(30%; n = 4,443)
Phenoxymethylpenicillin (27%; n = 719) Clarithromycin (24%; n = 228) Cefadroxil (16%; n = 145)
Amoxicillin + clavulanic acid (14%; n = 131)
Cefadroxil
(18%; n = 2,598)
Amoxicillin (27%; n = 719) Amoxicillin +
clavulanic acid (13%; n = 339)
Phenoxymethylpenicillin














Table 3 The frequency of prescriptions for systemic antibiotics per unique child prescribed in 2007
Number of prescriptions for
systemic antibiotics for child
per year
Frequency




1 prescription 51849 57.67 57.67
2 prescriptions 21235 23.62 81.29
3 prescriptions 9105 10.13 91.42
4 prescriptions 4128 4.59 96.01
5 prescriptions 1898 2.11 98.12
6 prescriptions 892 0.99 99.11
7 prescriptions 413 0.46 99.57
8 or more prescriptions 387 0.43 100
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of antibiotic resistance among outpatient pathogens
(e.g. Estonia) narrow spectrum penicillins could be used
instead of wide spectrum agents. The reasons why Estonian
physicians tend to prescribe wide spectrum agents have not
been systematically studied but the likely reasons could in-
volve the relatively liberal guideline recommendations. For
example, for acute tonsillitis, the Estonian guidelines, in
addition to phenoxymethylpenicillin recommend amoxicil-
lin despite the fact that S. pyogenes is uniformly susceptible
to penicillin (Hraoui et al. 2011). Other reasons could in-
volve the pressure from parents to receive the newest
agents, a limited option for etiologic diagnosis in out-
patient setting, the promotional activities of pharma-
ceutical industry, the lack of detailed knowledge due
to poor dissemination of guidelines or simply poor ad-
herence to guidelines (Hedin et al. 2006). The latter rea-
son could apparently be supported by the significant
amount (20%) of antibiotic prescriptions for acute
bronchitis, a disease not requiring antibiotic treatment
at all. Poor adherence to guidelines is also suggested
by the wide use of macrolides in Estonia although they
are only recommended for patients with penicillin al-
lergy or high use of oral cephalosporins, which are the
second or third choice agents according to the Estonian
guideline. We also show that in Estonia 65% of prescrip-
tions for trimetoprim-sulfamethoxazol were for acute
upper respiratory infections despite the indications be-
ing exacerbation of chronic bronchitis and genitouri-
nary infections.
Secondly, macrolides were extensively used in Estonia
vs. Sweden, accounting for 24% and 8% of all prescrip-
tions, respectively. The extended use of macrolides has
been related to increased carriage of penicillin non-
susceptible S.pneumoniae (Lusini et al. 2009) and the
inappropriate prescription of macrolides was one of
the targets for the STRAMA programme (Mölstad et al.
2008). The choice of macrolide also differed between
countries, clarithromycin predominating in Estonia while
the parent drug erythromycin was mainly used in Sweden.The preference of clarithromycin by Estonian prescribers
could possibly be explained by the easier administration
scheme - twice as compared to four times daily. Slightly
better tolerability in terms of gastrointestinal side effects
of clarithromycin compared to erythromycin has also been
reported (Lee et al. 2008).
Similar to other studies (Otters et al. 2004;
Finkelstein et al. 2000) almost a half of prescriptions
were made for respiratory tract infections like bron-
chitis, laryngitis, pharyngitis, AOM and sinusitis
which rarely are caused by bacteria - and for which
Estonian guidelines recommend not to use antibi-
otics or - for AOM - suggest to use ‘wait and see
strategy’ in children above 2. The reasons for this
non-adherence to guidelines are probably similar to
those suggested above but they have not been sys-
tematically studied.
Study strengths and limitations
The strength of this study is the lack of selection
bias as the databases cover the entire paediatric pop-
ulations in Estonia and Sweden. Although the data
collected in Estonia are more detailed than that col-
lected in Sweden, the method and reliability of data
collection is similar between the countries, offering
the potential for comparative estimates of the extent
of antibiotic use by age groups.
An apparent weakness of the study comes from
the fact that the Swedish data collection is not
diagnose-linked so we were not able to assess the
guideline adherence in Sweden.
Nor was it possible to describe between-country
variability of dose regimens and duration of treat-
ment. In order to study between-country variability
in treatment practices including choice of antibiotics
for different conditions, a prospective study would
be required.
One possible limitation could be the fact that we
used only data from one year. As our main aim was
to compare the prescription preferences of paediatric
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years than the total consumption (Kiivet et al. 1998;
Sharland 2007) we assume that this will not affect
the reliability of our study.
Conclusion
The low overall consumption of antibiotics is no in-
dicator of appropriate paediatric antibiotic prescrib-
ing. The higher rate of antibiotic use in Estonia and
the apparent high use of extended spectrum antibi-
otics emphasizes the need for national activities
similar to the Swedish STRAMA programme in
order to prevent further misuse, including the imple-
mentation of clinical pharmacy services. Guidelines
for the treatment of infectious diseases should be
regularly updated and actively distributed among all
prescribing physicians. Also, auditing activities should
focus on rational use of antibiotics and compliance to
evidence based guidelines.
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